New hope for incurable blood cancers: experimental CAR-T therapy enters trial
NCT ID NCT07070323
Summary
This study is testing a new type of personalized immune cell therapy, called CD5-CAR T cells, for people with aggressive T-cell blood cancers that have come back or not responded to standard treatments. The main goals are to find a safe and effective dose and to see if the therapy can shrink or eliminate the cancer. The study will enroll up to 54 children and adults aged 1 to 70 who have no other curative options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
-
Shanghai Liquan Hospital
RECRUITINGShanghai, Shanghai Municipality, 201418, China
-
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITINGChengdu, Sichuan, 610083, China
-
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
RECRUITINGShanghai, Shanghai Municipality, 200435, China
Conditions
Explore the condition pages connected to this study.